According to filings with the U.S. Securities and Exchange Commission, PTC Therapeutics is raising $35,897,425.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Stuart Peltz played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About PTC Therapeutics
PTC is a science-driven, patient-centered biopharmaceutical company focused on discovering, developing & commercializing medicine for patients with rare and serious disease. Over the last 25 years, everything we’ve done, every study, every experiment, every investment is made first and foremost to change the course of rare diseases for the lives of our patients. PTC is committed to providing access to best-in-class treatments for patients with little to no treatment options. This mission underpins our focus on the discovery, development, and global commercialization of clinically differentiated medicines for those with rare diseases. As a science-driven, global pharmaceutical company, we combine clinical and scientific expertise with groundbreaking science and technology. We work hard to provide broad access to our life-changing treatments. What drives us is our passion to provide patients with more moments with their families.

To learn more about PTC Therapeutics, visit http://www.ptcbio.com/

Contact:
Stuart Peltz, Chief Executive Officer
908-222-7000
https://www.linkedin.com/in/peltz-stuart-733176b/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.